Information Provided By: 
Fly News Breaks for February 5, 2019
MRNA
Feb 5, 2019 | 11:32 EDT
After Moderna announced the dosing of the first subject in a Phase 1 clinical trial evaluating the safety and tolerability of escalating doses of mRNA-1944, Piper Jaffray analyst Edward Tenthoff said he sees an important read-through from this data, expected in the first half of 2019, to the rest of Moderna's orphan disease pipeline. The analyst, who thinks mRNA technology is ideally suited to address short-comings of Enzyme Replacement Therapy, keeps an Overweight rating and $24 price target on Moderna shares.
News For MRNA From the Last 2 Days
There are no results for your query MRNA
